## VI. PRODUCT TESTING AND REMEDIATION COSTS

Pacific Cannabis Group's 4.2% historical product testing failure rate and pending $500,000-$2,000,000 pesticide contamination lawsuit create both immediate liability exposure and ongoing operational compliance risks requiring substantial remediation investment. Across Target's eight-state footprint, mandatory testing requirements for potency, contaminants, and microbiological impurities function as the regulatory backstop preventing adulterated cannabis products from reaching consumers, and failures trigger mandatory product destruction, revenue loss, regulatory scrutiny, and potential tort liability. This section quantifies Target's testing compliance gaps, analyzes remediation costs and return on investment, examines product liability exposure under state tort law, and provides contract language for allocation of pre-closing and post-closing testing liabilities.

### A. Mandatory State Testing Requirements — Strict Compliance Prerequisite to Commercial Distribution

All eight states where Target operates impose statutory testing mandates as a condition of licensure, requiring licensed third-party laboratories to analyze representative samples from each production batch before retail distribution.¹ Testing protocols vary by state but universally require analysis for cannabinoid potency, pesticide residues, heavy metals, microbial contaminants, and residual solvents. Failure to test, or distribution of products that fail testing parameters, constitutes grounds for product recall, license discipline, civil fines, and potential criminal prosecution for distribution of adulterated products.

#### 1. California Testing Requirements — Most Stringent Multi-Analyte Protocol

California Business and Professions Code § 26100 mandates that all cannabis products undergo comprehensive testing by a licensed Type 8 testing laboratory before sale.² The California Department of Cannabis Control (DCC) requires analysis for:

**Cannabinoid Potency** (Cal. Code Regs. tit. 16, § 5724): Total THC and total CBD content measured in milligrams per gram or per package, with maximum variance of ±15% from labeled amount. Products exceeding variance thresholds must be relabeled or destroyed.³

**Pesticide Residues** (Cal. Code Regs. tit. 16, § 5719): Testing for 66 specific pesticide active ingredients using liquid chromatography-mass spectrometry (LC-MS) or gas chromatography-mass spectrometry (GC-MS). California maintains Category I pesticides (prohibited entirely) and Category II pesticides (permitted with specific action levels). Detection of any Category I pesticide requires mandatory product destruction.⁴

**Heavy Metals** (Cal. Code Regs. tit. 16, § 5721): Testing for arsenic, cadmium, lead, and mercury using inductively coupled plasma mass spectrometry (ICP-MS). Action levels: lead <0.5 μg/g, arsenic <1.5 μg/g, cadmium <0.5 μg/g, mercury <3.0 μg/g.⁵

**Microbial Impurities** (Cal. Code Regs. tit. 16, § 5720): Analysis for *Aspergillus* species (*A. fumigatus*, *A. flavus*, *A. niger*, *A. terreus*), *E. coli*, *Salmonella* species, and total aerobic bacterial count. Any detection of *Salmonella* or *Aspergillus* requires destruction; elevated *E. coli* or total bacteria counts require remediation.⁶

**Residual Solvents** (Cal. Code Regs. tit. 16, § 5723): For manufactured products involving extraction (vape cartridges, concentrates, edibles), testing for Category I solvents (benzene, trichloroethylene), Category II solvents (methanol, acetone, hexane), and Category III solvents (butane, heptane, propane). Products exceeding solvent limits require destruction.⁷

**Mycotoxins** (Cal. Code Regs. tit. 16, § 5722): Testing for aflatoxins (B1, B2, G1, G2) and ochratoxin A. Total aflatoxin limit: 20 μg/kg. Products exceeding limits require destruction.⁸

California's phased implementation created initial testing backlogs, but as of 2024, turnaround times stabilized at 5-7 business days for standard testing, with laboratory costs ranging from $300-$800 per batch depending on product category (flower, concentrates, edibles).

#### 2. Colorado Testing Requirements — Homogeneity Analysis for Infused Products

Colorado Revised Statutes § 44-10-701 requires all retail marijuana products to undergo testing by a licensed testing facility before sale.⁹ Colorado's Marijuana Enforcement Division (MED) mandates analysis for potency, contaminants, and homogeneity. Colorado regulations impose additional requirements beyond California's framework for infused products (edibles, topicals, beverages), requiring homogeneity testing to ensure cannabinoid distribution throughout the product is uniform.¹⁰ This prevents "hot spots" where single servings contain excessive THC concentrations. Colorado's testing mandate covers:

- **Cannabinoid potency**: Total THC, total CBD, THCA, and CBDA content verification
- **Microbial contaminants**: *E. coli*, *Salmonella*, total yeast and mold count, *Aspergillus* species
- **Residual solvents**: For concentrates and extracts (butane, propane, hexane, ethanol)
- **Pesticide screening**: Testing for 35 pesticide active ingredients prohibited by Colorado Department of Agriculture
- **Heavy metals**: Arsenic, cadmium, lead, mercury
- **Mycotoxins**: Aflatoxin B1, B2, G1, G2
- **Homogeneity**: For edibles and infused products, coefficient of variation analysis confirming uniform cannabinoid distribution¹¹

Colorado MED regulations permit remediation of certain failures: products exceeding heavy metal limits may be extracted and processed into concentrates if contamination levels reduce below action limits after processing.¹²

#### 3. Other State Testing Requirements — Regional Variations

**Oregon** (ORS Chapter 475C; OAR 333-007-0300 to 333-007-0490): Oregon Liquor and Cannabis Commission (OLCC) requires testing for potency, pesticides (59 analytes), solvents, moisture content, water activity, and microbial contaminants. Oregon permits pre-harvest testing for certain pesticide screening to catch contamination before harvest.¹³

**Washington** (RCW 69.50.348; WAC 314-55-102): Washington State Liquor and Cannabis Board (WSLCB) mandates testing for potency, moisture content, foreign matter, microbial contaminants, mycotoxins, heavy metals, pesticides (and herbicides), and residual solvents. Washington testing laboratories must be ISO/IEC 17025:2017 accredited.¹⁴

**Nevada** (NAC 453A.700 to 453A.730): Nevada Cannabis Compliance Board (CCB) requires independent laboratory testing for potency, moisture content, foreign material, microbial contaminants, mycotoxins, heavy metals, pesticides, and residual solvents. Nevada permits limited remediation via re-extraction if contamination is due to processing errors.¹⁵

**Arizona** (A.R.S. § 36-2803.01; A.A.C. R9-17-404.05): Arizona Department of Health Services requires testing for potency, pesticides, heavy metals, mycotoxins, and microbial contaminants. Arizona regulations require batch testing (not just sample testing), increasing testing volume and costs.¹⁶

**Massachusetts** (M.G.L. c. 94G, § 14; 935 CMR 500.160): Massachusetts Cannabis Control Commission (CCC) requires testing for potency, pesticides, heavy metals, mycotoxins, residual solvents, microbial impurities, and filth/foreign matter. Massachusetts mandates testing of both harvest batches and manufactured product batches.¹⁷

**Illinois** (410 ILCS 705/15-25; 8 Ill. Adm. Code 1300.410): Illinois Department of Financial and Professional Regulation requires testing for potency, pesticides (Category I and II), microbial contaminants, mycotoxins, residual solvents, heavy metals, and foreign material. Illinois regulations impose strict chain-of-custody requirements for samples transported to laboratories.¹⁸

#### 4. Third-Party Laboratory Certification Requirements — Independence Mandate

All eight states prohibit vertical integration between cultivation/manufacturing licensees and testing laboratories to prevent conflicts of interest. Testing must be performed by independent, state-licensed laboratories that meet accreditation standards.¹⁹ Most states require ISO/IEC 17025:2017 accreditation, which mandates:

- **Quality management systems**: Documented standard operating procedures (SOPs), proficiency testing, method validation
- **Equipment calibration**: Annual calibration of analytical instruments (LC-MS, GC-MS, ICP-MS) traceable to NIST standards
- **Personnel qualifications**: Laboratory directors with degrees in chemistry, biology, or related sciences; analysts with documented training
- **Blind proficiency testing**: Participation in third-party proficiency testing programs to verify accuracy²⁰

Laboratory accreditation serves as regulatory prerequisite to licensure; loss of accreditation triggers immediate suspension of testing authority, requiring retesting of all products released during the non-compliant period.

[XREF:TESTING → STATE LICENSING: Laboratory accreditation failures affecting Target's testing partners create supply chain disruptions that regulators scrutinize during license transfer reviews]

### B. Target's Testing Failure Rate — 4.2% Historical Rate Exceeds Industry Benchmarks

Due diligence materials provided by Target document a **4.2% testing failure rate** across all eight states over the trailing 24-month period (January 2023–December 2024). This equates to approximately 4,320 failed test batches out of 102,857 total batches tested, based on Target's production volume of 103,000 kg annually and average batch sizes of 1 kg (flower) to 50 kg (trim/shake for extraction).²¹

#### 1. Failure Rate Analysis by Contaminant Category

Target's failure profile breaks down as follows:

| Contaminant Category | Failed Batches | % of Total Failures | Primary Cause |
|---------------------|----------------|-------------------|---------------|
| **Pesticide residues** | 2,592 (60%) | 2.52% of all batches | Unapproved pesticide application; cross-contamination from adjacent grows |
| **Microbial contamination** | 1,296 (30%) | 1.26% of all batches | Inadequate climate control; post-harvest mold growth during drying/curing |
| **Heavy metals** | 259 (6%) | 0.25% of all batches | Contaminated fertilizers; water source contamination (arsenic, cadmium) |
| **Potency variance** | 173 (4%) | 0.17% of all batches | Labeling errors; inadequate homogeneity in edibles/infused products |
| **TOTAL** | **4,320** | **4.2%** | — |

**Industry Benchmarking**: Based on third-party cannabis industry compliance data, mature cultivators in established markets typically achieve failure rates below 1.5%, with best-in-class operators at <0.5%.²² Target's 4.2% failure rate represents approximately **2.8x the industry median**, indicating systemic quality control deficiencies rather than isolated incidents.

#### 2. Financial Impact of Testing Failures — Revenue Loss and Destruction Costs

Testing failures require mandatory product destruction under state regulations, creating direct revenue loss:

**Revenue Loss Calculation**:
- Failed batches: 4,320 per 24 months = 2,160 batches annually
- Average batch size: 5 kg (weighted average of flower, trim, concentrates)
- Total destroyed product: 10,800 kg annually
- Average wholesale price: $1,200/kg (blended rate)
- **Annual revenue loss**: $12,960,000

**Destruction and Testing Costs**:
- Testing cost per batch: $450 average (range: $300-$800)
- Failed batch testing costs: $1,944,000 annually (testing fees paid before failure discovered)
- Destruction services: $15/kg × 10,800 kg = $162,000 annually
- **Total testing-related costs**: $2,106,000 annually

**Combined Annual Impact**: $15,066,000 (revenue loss + testing/destruction costs)

This $15.1 million annual impact represents approximately **5.3% of Target's annual revenue** (assuming $285 million based on 103,000 kg production at blended pricing), significantly eroding profitability and creating recurring regulatory scrutiny.

[XREF:TESTING → VALUATION: $15.1M annual revenue loss from testing failures justifies quality control system remediation investment; failure to remediate creates ongoing EBITDA drag affecting purchase multiple]

#### 3. Regulatory Consequences of Elevated Failure Rates — License Scrutiny

While isolated testing failures are routine in cannabis cultivation (contamination risks inherent to agricultural production), **sustained elevated failure rates above 3% trigger enhanced regulatory oversight** in most jurisdictions. California DCC guidance documents indicate that licensees with failure rates exceeding twice the state median (California median: 1.8%) may face:

- **Compliance inspections**: Unannounced facility inspections focusing on cultivation practices, pesticide storage, sanitation protocols
- **Corrective action plans**: Mandatory submission of written corrective action plans detailing specific steps to reduce failure rates, with quarterly progress reporting
- **Probationary status**: License placed on probationary status if failure rates do not improve within 6 months of corrective action plan submission
- **Fines and penalties**: Civil penalties ranging from $5,000 to $30,000 per violation (per Cal. Bus. & Prof. Code § 26030)
- **License suspension**: Repeated failures to implement corrective actions may result in 30-day license suspension²³

During merger and acquisition license transfer reviews, state regulators explicitly consider the target entity's compliance history, including testing failure rates, as evidence of operational competence. Elevated failure rates may delay approval, impose additional conditions precedent (such as pre-closing remediation), or result in denial if regulators lack confidence in acquirer's ability to remedy operational deficiencies.²⁴

[XREF:TESTING → STATE LICENSING: 4.2% failure rate creates regulatory scrutiny risk during license transfer applications; may require pre-closing corrective action plan submission in CA, CO, MA]

### C. Remediation Costs — One-Time Systems Investment and Ongoing QA/QC Enhancement

Reducing Target's testing failure rate from 4.2% to industry best-practice levels (<1%) requires systematic upgrades to cultivation practices, quality assurance protocols, and post-harvest handling procedures. Based on industry benchmarking and consultant estimates for multi-state cannabis operators, remediation encompasses:

#### 1. One-Time Capital Investment: $4.2M–$7.1M

**Cultivation Systems Upgrades** ($2.1M–$3.5M):
- **Integrated Pest Management (IPM) systems**: Installation of automated monitoring systems (sticky traps, pheromone sensors, real-time pest identification cameras) across all cultivation facilities to detect pest presence before pesticide application becomes necessary. Cost: $500,000–$800,000.
- **Climate control system upgrades**: HVAC system retrofits to maintain precise temperature (68–78°F) and humidity (45–55% RH during flowering) to prevent microbial growth. Cost: $1,200,000–$2,000,000.
- **Water filtration systems**: Reverse osmosis (RO) or activated carbon filtration systems at all cultivation facilities to remove heavy metal contamination from irrigation water. Cost: $400,000–$700,000.²⁵

**Quality Control Laboratory Build-Out** ($1.5M–$2.3M):
- **In-house pre-screening laboratories**: Establish internal QC labs at each major cultivation facility for rapid screening (handheld XRF for heavy metals, ATP bioluminescence for microbial load, visual microscopy for mold/pests) before sending samples to third-party licensed laboratories. Reduces volume of failed batches sent to expensive third-party testing. Cost: $1,500,000–$2,300,000 for 8 facilities.²⁶

**Standard Operating Procedures (SOPs) and Training** ($600K–$1.3M):
- **Cultivation SOPs**: Document and implement written standard operating procedures for pest management, fertilizer application, irrigation, sanitation, and post-harvest handling.
- **Employee training programs**: Comprehensive training for cultivation staff (120 employees across 8 states) on IPM, early contamination detection, proper pesticide application (if approved), and harvest/drying/curing best practices.
- **Consultant engagement**: Engage specialized cannabis cultivation consultants (e.g., SC Labs, Steep Hill, CannaSafe) to conduct facility audits, develop customized SOPs, and provide on-site training. Cost: $600,000–$1,300,000.²⁷

**Total One-Time Investment**: $4,200,000–$7,100,000

#### 2. Ongoing Annual Costs: $1.5M–$2.5M

**Enhanced Quality Assurance/Quality Control Personnel** ($900K–$1.5M annually):
- Hire dedicated QA/QC managers at each major cultivation facility (8 positions at $75K–$95K salary + benefits = $600K–$760K)
- Hire corporate-level Chief Quality Officer responsible for multi-state quality systems and regulatory compliance ($180K–$240K salary + benefits)
- Additional laboratory technicians for in-house pre-screening (12 positions at $45K–$60K = $540K–$720K)
- **Total personnel costs**: $900,000–$1,500,000 annually²⁸

**Increased Testing Costs** ($400K–$700K annually):
- Implementation of pre-harvest testing (testing immature plants to detect contamination before harvest rather than post-harvest)
- Duplicate testing at two independent laboratories for batches approaching contamination action levels (to verify results and avoid false positives)
- **Incremental testing costs**: $400,000–$700,000 annually²⁹

**Continuous Improvement Programs** ($200K–$300K annually):
- Ongoing consultant engagement for quarterly audits and continuous improvement initiatives
- Proficiency testing and method validation for in-house laboratories
- Industry certification programs (e.g., ASTM D37 Committee on Cannabis Standards, Cannabis Science Conference training)
- **Continuous improvement budget**: $200,000–$300,000 annually³⁰

**Total Ongoing Annual Investment**: $1,500,000–$2,500,000

#### 3. Return on Investment — Failure Rate Reduction Saves $3M–$5M Annually

If remediation initiatives successfully reduce Target's failure rate from 4.2% to best-practice levels (<1%), the financial benefits are substantial:

**Reduced Revenue Loss**:
- Current failure rate: 4.2% (10,800 kg destroyed annually)
- Target failure rate: 0.8% (1,680 kg destroyed annually)
- **Reduction**: 9,120 kg saved annually
- Revenue recovery: 9,120 kg × $1,200/kg = **$10,944,000 annually**

**Reduced Testing/Destruction Costs**:
- Current failed batch testing costs: $1,944,000 annually
- Target failed batch testing costs: $311,040 annually (0.8% failure rate)
- **Savings**: $1,632,960 annually

**Total Annual Benefit**: $12,576,960

**Net Annual Savings** (after deducting ongoing costs): $12,576,960 – $2,000,000 (midpoint ongoing costs) = **$10,576,960**

**Payback Period**: $5,650,000 (midpoint one-time investment) ÷ $10,576,960 annual savings = **0.53 years (6.4 months)**

**5-Year NPV** (12% discount rate):
- One-time cost: $5,650,000
- Annual savings: $10,576,960 for 5 years
- NPV = –$5,650,000 + $10,576,960 × 3.605 (PV annuity factor) = **$32,428,868**

**ROI**: 5.7x over 5 years

This exceptional ROI (payback in 6.4 months) makes quality control remediation one of the highest-priority post-closing initiatives, substantially exceeding returns from most operational improvement investments.

[XREF:TESTING → VALUATION: Quality control remediation NPV of $32.4M justifies immediate post-closing investment; failure to remediate creates ongoing $15M annual EBITDA drag reducing enterprise value by $54M (at 12% discount rate)]

### D. Product Liability Exposure — Pending California Case and Ongoing Tort Risk

Target faces one pending product liability lawsuit in California and ongoing exposure to future claims arising from contaminated cannabis products. Unlike traditional consumer products, cannabis product liability cases are infrequent (only 3-5 reported cases annually nationwide), primarily because most cases settle confidentially to avoid precedent, federal court jurisdiction is unavailable (cannabis remains federally illegal), and state courts in some jurisdictions have been reluctant to adjudicate "illegal product" claims.³¹ However, California courts have uniformly rejected the federal illegality defense, applying traditional state tort theories to cannabis products.³²

#### 1. Pending California Case — *Doe v. Pacific Cannabis Group* (Super. Ct. Alameda County)

**Procedural Posture**: Complaint filed September 2024; discovery ongoing; Target estimates settlement range $500,000–$2,000,000.³³

**Allegations**: Plaintiff, a California medical marijuana patient, purchased cannabis flower from Target's Oakland dispensary in June 2024. Plaintiff alleges the product was contaminated with myclobutanil (Eagle 20 fungicide), a Category I prohibited pesticide in California. Plaintiff claims respiratory illness, nausea, and headaches after consuming the product, with emergency room treatment documented. Plaintiff's counsel obtained independent laboratory testing confirming myclobutanil presence at 1.8 μg/g (California action level: 0 μg/g for Category I pesticides).³⁴

**Claims Asserted**:
1. **Strict products liability** (Restatement (Second) of Torts § 402A): Product was defective (pesticide contamination), defect existed when product left Target's control, defect caused plaintiff's injury
2. **Negligence**: Target failed to implement adequate cultivation and testing protocols to prevent contamination
3. **Breach of express warranty**: Target marketed products as "lab-tested" and "clean," creating express warranty that product was free from prohibited pesticides
4. **Breach of implied warranty of merchantability**: Product was unfit for ordinary use (human consumption)³⁵

**Target's Defenses**:
- **Regulatory compliance defense**: Product passed mandatory California DCC laboratory testing; licensed third-party laboratory certified product compliant with all state standards
- **Third-party lab negligence**: Contamination should have been detected by state-licensed laboratory; laboratory bears primary responsibility
- **Causation**: Plaintiff has pre-existing respiratory conditions (asthma, COPD); cannot establish that contamination caused alleged injuries rather than underlying conditions
- **Comparative fault**: Plaintiff's smoking method (combustion at high temperatures) may have created byproducts unrelated to pesticide residues³⁶

**Likelihood of Success Analysis**:

| Theory | Plaintiff's Burden | Target's Defense Strength | Probable Outcome |
|--------|-------------------|--------------------------|------------------|
| **Strict liability** | Prove defect existed and caused injury | Moderate (regulatory compliance not complete defense in CA)³⁷ | **Plaintiff favored** if causation proven |
| **Negligence** | Prove breach of duty to test/screen | Strong (used licensed laboratory per statute) | **Target favored** |
| **Express warranty** | Prove product failed to conform to "lab-tested" representation | Weak (product WAS lab-tested; false negative not false representation) | **Target strongly favored** |
| **Causation** | Medical causation linking contamination to respiratory illness | **Critical battleground**; plaintiff must exclude alternative causes | **Most contested issue** |

**Settlement Considerations**: Target's $500,000–$2,000,000 settlement estimate aligns with industry precedent. Similar cannabis contamination cases have settled in this range:

- *McCullough v. LivWell Enlightened Health* (Colo. Dist. Ct. 2018): Myclobutanil contamination case settled for estimated $800,000–$1,500,000 after 18 months of litigation³⁸
- *Doe v. [Redacted Cannabis Company]* (Wash. Super. Ct. 2020): Sale to minor case settled for $1,200,000 (higher due to regulatory violations beyond product defect)³⁹
- Median settlement range for pesticide contamination cases: $500,000–$1,200,000 absent severe injuries⁴⁰

**Insurance Coverage**: Target maintains product liability insurance with $10,000,000 aggregate limit and $2,500,000 per-occurrence limit. The pending California case was timely reported to insurer, and insurer has appointed defense counsel but reserved rights on coverage (asserting potential pollution exclusion for pesticide contamination). If insurer successfully invokes pollution exclusion, Target would bear full settlement/judgment amount.⁴¹

#### 2. Ongoing Product Liability Risk — $500K–$1M Annual Exposure

Beyond the pending case, Target faces ongoing exposure to future product liability claims arising from its elevated 4.2% testing failure rate. Each failed batch that reaches consumers (false negatives not caught by testing laboratories) creates potential claims.

**Exposure Estimation**:
- Testing laboratories report false negative rates of 0.1%–0.5% (products that pass testing but actually contain contaminants above action levels)⁴²
- Applying 0.3% false negative rate to Target's 98,537 batches that passed testing annually: **296 contaminated batches reached consumers**
- Percentage of contaminated batches causing consumer injury: estimated 0.5%–2% (most contamination at levels causing no acute symptoms)
- **Estimated annual claims**: 1.5–6 claims annually
- Average settlement per claim: $300,000–$500,000
- **Annual exposure**: $450,000–$3,000,000 (probability-weighted midpoint: $750,000)

**NPV Calculation** (5-year exposure, 40% probability of claims materializing, 12% discount rate):
- Annual exposure: $750,000
- Probability-adjusted: $750,000 × 0.40 = $300,000 annually
- NPV = $300,000 × 3.605 (5-year annuity factor) = **$1,081,500**

Adding pending case ($1,200,000 midpoint settlement) yields **total product liability NPV of $2,281,500**, rounded to $1.53M in base case analysis assuming partial insurance recovery.⁴³

[XREF:TESTING → INSURANCE: Product liability exposure of $2.28M over 5 years depends on $10M aggregate coverage adequacy; pollution exclusion risk may shift $1.2M pending claim to Target]

#### 3. Regulatory Consequences of Product Liability Claims — Recall and License Impact

Product liability lawsuits trigger regulatory reporting obligations and may result in mandatory recalls if state agencies determine contaminated products remain in retail inventory. California Business and Professions Code § 26070 requires licensees to notify DCC within 24 hours of becoming aware that a cannabis product "may present a health or safety risk."⁴⁴ Pending litigation alleging contamination typically triggers this notification requirement.

Upon notification, DCC may issue a **mandatory recall order** requiring:
- Immediate cessation of sales of all products from the implicated batch
- Public notice to consumers via DCC website, licensee website, and point-of-sale signage
- Retrieval of all products in distribution chain (wholesale, retail inventory, consumer returns)
- Destruction of all recalled products under regulatory supervision
- Root cause analysis and corrective action plan submission⁴⁵

**Recall Costs**: Industry data indicates average recall costs of $50,000–$200,000 per recall (depending on distribution scope), including:
- Notification costs (website, signage, customer contact)
- Product retrieval logistics
- Destruction fees
- Lost revenue from destroyed inventory
- Staff time for recall coordination⁴⁶

**License Transfer Impact**: During license transfer reviews, state regulators scrutinize recall history as evidence of operational competence. California DCC application forms require disclosure of all recalls in the preceding 3 years. Multiple recalls, or recalls indicating systemic quality control failures (rather than isolated incidents), may result in transfer application denial or imposition of conditional approval requiring corrective action plan implementation before operational control transfers.⁴⁷

[XREF:TESTING → STATE LICENSING: Pending product liability case creates recall risk during license transfer period; DCC may impose pre-closing conditions requiring quality control upgrades]

### E. Insurance Coverage Adequacy — $10M Aggregate Limit vs. Industry Benchmarks

Target's current product liability insurance policy provides $10,000,000 aggregate limit with $2,500,000 per-occurrence sublimit. This coverage must be evaluated against Target's exposure profile.

**Industry Benchmarks**: Cannabis multi-state operators with comparable revenue ($200M–$400M annually) typically maintain product liability coverage of $15M–$25M aggregate, reflecting:
- Higher litigation costs in cannabis industry due to novel legal issues and lack of precedent
- Potential for class action claims (e.g., if contamination affects multiple batches, creating claims from hundreds of consumers)
- Pollution exclusion disputes requiring separate legal representation beyond defense costs
- Limited insurer competition in cannabis space, making replacement coverage difficult to obtain⁴⁸

**Coverage Gap Analysis**:

| Scenario | Exposure | Current Coverage | Gap |
|----------|----------|------------------|-----|
| **Single pending case** | $500K–$2M | $2.5M per occurrence | ✓ Adequate |
| **Annual baseline claims** (3 cases) | $1.5M annually | $10M aggregate | ✓ Adequate |
| **Multiple contamination events** (systemic failure) | $5M–$15M | $10M aggregate | ⚠️ Potential $5M gap |
| **Class action** (widespread contamination) | $25M–$50M | $10M aggregate | ❌ Substantial gap |

**Recommendation**: Increase product liability coverage to **$20M aggregate** post-closing, particularly if quality control remediation efforts experience implementation delays. Premium increase estimated at $150,000–$300,000 annually for additional $10M in coverage.⁴⁹

[XREF:TESTING → INSURANCE: Quality control remediation investment ($5.65M) provides better risk mitigation than incremental insurance ($250K/year for $10M additional coverage); prioritize operational improvements]

### F. Risk Assessment and Mitigation Strategy

#### Summary Risk Table

| Finding | Severity | Probability | Gross Exposure | Weighted Impact | Mitigation Strategy |
|---------|----------|-------------|----------------|-----------------|---------------------|
| **4.2% testing failure rate** | HIGH | 100% (ongoing) | $15.1M annual revenue loss | $15.1M annually | Quality control remediation ($5.65M one-time + $2M annual) |
| **Pending product liability case** | MEDIUM | 80% (settlement likely) | $500K–$2M | $1.2M | Insurance defense; settle within policy limits |
| **Ongoing product liability exposure** | MEDIUM | 40% (future claims) | $750K annually | $300K annually | Enhanced QC reduces claim frequency |
| **Regulatory recall risk** | MEDIUM | 30% (if pending case escalates) | $100K–$500K per recall | $180K | Proactive quality improvements reduce recall triggers |
| **Insurance coverage gap** | LOW | 10% (catastrophic event) | $15M–$40M | $2.75M | Increase coverage to $20M aggregate ($250K annual premium) |

**Aggregate NPV Impact** (5-year horizon, 12% discount rate):
- Testing failure revenue loss (pre-remediation): $15.1M × 3.605 = $54.44M
- Pending product liability case: $1.2M (assumed Year 1 settlement)
- Ongoing product liability: $0.3M × 3.605 = $1.08M
- Recall risk: $0.18M × 3.605 = $0.65M
- **Total NPV exposure**: **$57.37M**

**Post-Remediation NPV**:
- Testing failure revenue loss (post-remediation): $1.5M annually × 3.605 = $5.41M
- One-time remediation cost: $5.65M
- Ongoing remediation cost: $2M annually × 3.605 = $7.21M
- Product liability reduction (80% reduction due to lower failure rate): $0.06M × 3.605 = $0.22M
- **Total post-remediation NPV cost**: **$18.49M**

**Net Remediation Benefit**: $57.37M – $18.49M = **$38.88M NPV savings** over 5 years

This $38.88 million NPV benefit from quality control remediation justifies immediate post-closing investment as the highest-ROI operational improvement initiative available.

#### Purchase Price Impact Recommendation

| Finding | Gross Exposure | Probability | Weighted Impact | Recommendation |
|---------|---------------|-------------|-----------------|----------------|
| Pending product liability case | $1.2M | 80% | $960K | Escrow holdback |
| Quality control remediation (one-time) | $5.65M | 100% | $5.65M | Purchase price reduction OR buyer funds post-closing |
| Ongoing testing failure revenue loss | $15.1M annual | 100% | Reflected in EBITDA | Already in valuation |

**Escrow Allocation**: Reserve **$2,000,000** of $15M total escrow (18-month duration) for product liability resolution. Release:
- $1,000,000 upon settlement of pending California case within policy limits (<$2M)
- $1,000,000 at 18-month expiration if no additional product liability claims filed

**Purchase Price Adjustment**: Quality control remediation costs ($5.65M one-time) should be **funded by acquirer post-closing** rather than purchase price reduction, because:
1. Remediation has 5.7x ROI, creating $32.4M NPV value for buyer
2. Failure to remediate perpetuates $15.1M annual revenue loss, reducing enterprise value by $54M
3. Seller lacks incentive to invest in remediation pre-closing if transaction pending
4. Acquirer has superior operational expertise to implement quality control systems⁵⁰

**Alternative Structure**: If seller resists $2M escrow, negotiate **joint remediation investment** where seller funds 50% ($2.8M) of one-time remediation costs pre-closing, with purchase price held constant. This aligns incentives and demonstrates seller's commitment to compliance.

### G. Draft Remediation and Indemnification Language

#### Section 6.18 — Product Testing and Quality Assurance

**(a) Testing Compliance Representation.** Seller represents and warrants that:

(i) All cannabis products manufactured, distributed, or sold by the Company during the 24-month period preceding the Closing Date underwent testing by licensed third-party testing laboratories as required by applicable state cannabis regulations in California, Colorado, Oregon, Washington, Nevada, Arizona, Massachusetts, and Illinois;

(ii) The Company's testing failure rate (defined as the percentage of tested batches failing to meet state-mandated action levels for potency, contaminants, microbials, or other parameters) for the 24-month period ending December 31, 2024, was 4.2% across all jurisdictions;

(iii) Schedule 6.18(a) sets forth a complete and accurate list of all testing failures during the 24-month period preceding the Closing Date, including: (A) batch identification number, (B) contaminant type and level detected, (C) state jurisdiction, (D) corrective action taken (product destruction, remediation, or other), and (E) any regulatory communications or enforcement actions arising from the failure;

(iv) Except as set forth on Schedule 6.18(a), the Company has not received any notices of violation, corrective action plans, or license discipline related to product testing compliance from any state cannabis regulatory authority during the 36-month period preceding the Closing Date;

(v) The Company maintains product liability insurance with coverage limits of not less than $10,000,000 aggregate and $2,500,000 per occurrence, and such insurance is in full force and effect as of the Closing Date.

**(b) Pending Product Liability Claim.** Seller acknowledges that the Company is a defendant in *Doe v. Pacific Cannabis Group*, Case No. RG24123456 (Super. Ct. Alameda County), alleging pesticide contamination and related personal injuries (the "**Pending Claim**"). Seller shall:

(i) Continue to defend the Pending Claim through Closing using insurance-appointed defense counsel;

(ii) Provide Buyer with weekly litigation status updates, including all pleadings, discovery responses, expert reports, and settlement communications;

(iii) Not settle the Pending Claim without Buyer's prior written consent (not to be unreasonably withheld if settlement is within policy limits);

(iv) Indemnify Buyer for all losses, liabilities, damages, and expenses (including attorneys' fees) arising from the Pending Claim to the extent such amounts exceed insurance coverage or are excluded from coverage due to pollution exclusions or other policy limitations.

**(c) Product Liability Indemnification Cap.** Notwithstanding Section 11.4 (General Indemnification Cap), Seller's indemnification obligations under Section 6.18(b) relating to the Pending Claim shall not exceed **$2,000,000** and shall terminate 24 months following the Closing Date. The parties acknowledge that amounts paid under this Section 6.18(c) shall be satisfied first from the Escrow Amount (as defined in Section 3.2) before any additional payment obligation arises.

**(d) Post-Closing Quality Control Remediation.** Buyer acknowledges that the Company's 4.2% testing failure rate exceeds industry benchmarks (<1.5%) and that substantial investment in quality control systems is required to achieve compliance with best practices. Buyer agrees to fund quality control remediation initiatives post-Closing, including:

(i) Integrated Pest Management (IPM) system upgrades at all cultivation facilities;

(ii) Climate control and water filtration system enhancements to reduce microbial contamination and heavy metal exposure;

(iii) In-house quality control laboratory build-out for pre-screening before third-party testing;

(iv) Standard operating procedure (SOP) development and employee training programs;

(v) Hiring of dedicated quality assurance/quality control personnel, including a Chief Quality Officer and facility-level QA managers.

Buyer's failure to implement quality control remediation shall not diminish Seller's indemnification obligations under this Section 6.18, and Buyer waives any claim that Buyer's post-Closing operational decisions contributed to product liability claims arising from pre-Closing contamination events.

**(e) Regulatory Recall Cooperation.** If any state cannabis regulatory authority issues a recall order for products manufactured or distributed by the Company prior to Closing, Seller shall:

(i) Reimburse Buyer for all reasonable costs incurred in complying with the recall order, including notification costs, product retrieval, destruction fees, and lost revenue from destroyed inventory (capped at $500,000 per recall event);

(ii) Cooperate with Buyer in responding to regulatory inquiries, including making former employees available for interviews and providing historical records;

(iii) Indemnify Buyer for any fines, penalties, or license discipline imposed by state regulatory authorities arising from pre-Closing product contamination events.

#### Section 3.2(c) — Escrow Allocation for Product Liability

Of the $15,000,000 Escrow Amount deposited at Closing, **$2,000,000** shall be allocated to product liability claims (the "**Product Liability Reserve**"). The Product Liability Reserve shall be released as follows:

(i) **$1,000,000** shall be released to Seller upon the earlier of: (A) final settlement or judgment in the Pending Claim (as defined in Section 6.18(b)) for an amount not exceeding $2,000,000 and covered by insurance, or (B) dismissal of the Pending Claim with prejudice;

(ii) **$1,000,000** shall be released to Seller 18 months following the Closing Date, provided that no additional product liability claims arising from pre-Closing contamination events have been asserted against the Company;

(iii) If the Pending Claim settles or results in judgment for an amount exceeding insurance coverage, Buyer may draw against the Product Liability Reserve for the excess amount (up to $2,000,000);

(iv) If additional product liability claims are asserted within 18 months of Closing and arise from pre-Closing contamination events, Buyer may draw against the Product Liability Reserve for defense costs and settlement/judgment amounts not covered by insurance (up to $2,000,000 aggregate across all claims).

#### Section 7.3 — Post-Closing Testing Protocol Enhancement Covenant

Within 120 days following the Closing Date, Buyer shall engage a qualified cannabis cultivation consultant (such as SC Labs, Steep Hill, or CannaSafe) to:

(i) Conduct comprehensive audits of all Company cultivation facilities to identify root causes of the 4.2% testing failure rate documented in Schedule 6.18(a);

(ii) Develop facility-specific corrective action plans addressing Integrated Pest Management (IPM), climate control, water quality, and post-harvest handling procedures;

(iii) Deliver written audit reports and corrective action plans to the California Department of Cannabis Control, Colorado Marijuana Enforcement Division, and other state regulatory authorities in jurisdictions where the Company's testing failure rate exceeded state median by more than 50% during the trailing 24-month period;

(iv) Provide quarterly progress reports to Buyer's Board of Directors documenting testing failure rate improvements and return on investment from quality control investments.

This covenant is included to demonstrate to state regulatory authorities reviewing license transfer applications that Buyer has committed to operational improvements addressing compliance deficiencies identified during due diligence.

---

## FOOTNOTES

1. See Cal. Bus. & Prof. Code § 26100 (West 2024) (California testing requirement); C.R.S. § 44-10-701 (Colorado testing requirement); ORS 475C.652 (Oregon testing requirement); RCW 69.50.348 (Washington testing requirement); Nev. Rev. Stat. § 453A.500 (Nevada testing requirement); A.R.S. § 36-2803.01 (Arizona testing requirement); M.G.L. c. 94G, § 14 (Massachusetts testing requirement); 410 ILCS 705/15-25 (Illinois testing requirement).

2. Cal. Bus. & Prof. Code § 26100(a) (West 2024) ("All manufactured cannabis and cannabis products, as defined by the department by regulation, shall be tested in accordance with this division and any regulation adopted pursuant to this division by a licensed testing laboratory.").

3. Cal. Code Regs. tit. 16, § 5724(a)-(b) (2024) (cannabinoid potency testing requirements and variance tolerances).

4. Cal. Code Regs. tit. 16, § 5719(a)-(d) (2024) (pesticide residue testing requirements; Category I pesticides prohibited entirely; detection requires destruction); see also California Department of Pesticide Regulation, *Cannabis Pesticide Guidance* (Oct. 2023), available at https://www.cdpr.ca.gov/docs/cannabis/index.htm.

5. Cal. Code Regs. tit. 16, § 5721(a)-(b) (2024) (heavy metals testing requirements and action levels).

6. Cal. Code Regs. tit. 16, § 5720(a)-(c) (2024) (microbial impurities testing requirements; *Aspergillus* and *Salmonella* detection requires destruction).

7. Cal. Code Regs. tit. 16, § 5723(a)-(d) (2024) (residual solvent testing requirements by solvent category).

8. Cal. Code Regs. tit. 16, § 5722(a)-(b) (2024) (mycotoxin testing requirements; aflatoxin limit 20 μg/kg).

9. C.R.S. § 44-10-701 (2024) ("All retail marijuana and retail marijuana products must be tested for contaminants, potency, and homogeneity at a licensed testing facility prior to sale.").

10. 1 Colo. Code Regs. § 212-3, Rule M 1103 (2024) (homogeneity testing requirements for infused products; coefficient of variation analysis).

11. *Id.*; see also Colorado Marijuana Enforcement Division, *Testing and Research Development Requirements*, available at https://sbg.colorado.gov/med/med-rules-regulations.

12. 1 Colo. Code Regs. § 212-3, Rule M 1104 (2024) (remediation protocols for certain failed batches).

13. OAR 333-007-0300 to 333-007-0490 (2024) (Oregon testing requirements); see also Oregon Liquor and Cannabis Commission, *Laboratory Testing Requirements*, available at https://www.oregon.gov/olcc/marijuana/Pages/default.aspx.

14. WAC 314-55-102 (2024) (Washington testing requirements; ISO/IEC 17025:2017 accreditation mandate).

15. Nev. Admin. Code §§ 453A.700-453A.730 (2024) (Nevada testing requirements and remediation protocols).

16. Ariz. Admin. Code § R9-17-404.05 (2024) (Arizona batch testing requirements).

17. 935 Mass. Code Regs. 500.160 (2024) (Massachusetts testing requirements for harvest and manufactured product batches).

18. 8 Ill. Adm. Code 1300.410 (2024) (Illinois testing requirements; chain-of-custody protocols).

19. See, e.g., Cal. Bus. & Prof. Code § 26070(a) (West 2024) ("A testing laboratory licensee shall be independent from all other licensees for whom the licensee conducts testing"); C.R.S. § 44-10-701(2) (similar Colorado independence requirement).

20. ISO/IEC 17025:2017, *General Requirements for the Competence of Testing and Calibration Laboratories* (International Organization for Standardization, 2017); see also California Department of Cannabis Control, *Testing Laboratory Licensing Requirements*, available at https://cannabis.ca.gov/.

21. Target due diligence materials provided to Acquirer on December 10, 2024, including *Pacific Cannabis Group Testing Failure Analysis, January 2023 – December 2024* (on file with counsel).

22. See *Cannabis Testing & Compliance Report 2024*, SC Labs (Feb. 2024) (industry survey of 1,200 licensed cultivators across 15 states; median failure rate 1.5%, best-in-class <0.5%); *2024 Cannabis Industry Quality Benchmarks*, Steep Hill Labs (March 2024) (similar findings).

23. California Department of Cannabis Control, *Enforcement Priorities and Corrective Action Plan Guidelines* (June 2023), available at https://cannabis.ca.gov/; see also Cal. Bus. & Prof. Code § 26030 (West 2024) (civil penalty authority $5,000-$30,000 per violation).

24. See Cal. Bus. & Prof. Code § 26051.5(b)(3) (West 2024) (DCC shall consider "compliance with licensing requirements" in reviewing transfer applications); California Department of Cannabis Control, *Owner Change Application Review Process* (Feb. 2024) (guidance document noting that elevated testing failure rates may trigger enhanced review).

25. Cost estimates based on third-party cannabis cultivation consultant proposals obtained during due diligence: SC Labs, *Quality Control System Upgrade Proposal for Pacific Cannabis Group* (Dec. 2024); CannaSafe Analytics, *Cultivation Remediation Cost Analysis* (Dec. 2024) (both on file with counsel).

26. *Id.*; see also *Cannabis Cultivation Facility Design and Operations*, 3d ed., by Ed Rosenthal & Robert Flannery (2023) (industry reference on in-house laboratory capabilities).

27. SC Labs, *supra* note 25; Steep Hill Labs, *Standard Operating Procedure Development Services Proposal* (Dec. 2024) (on file with counsel).

28. Salary estimates based on *2024 Cannabis Industry Compensation Survey*, Vangst Talent Network (March 2024) (reporting median salaries for QA/QC managers, Chief Quality Officers, and laboratory technicians in multi-state cannabis operations).

29. Testing cost estimates based on vendor quotations from licensed testing laboratories in Target's eight operating states, obtained during due diligence (Dec. 2024) (on file with counsel).

30. Cost estimates for continuous improvement programs based on consultant proposals, *supra* note 25; see also ASTM International, *ASTM D37 Committee on Cannabis Standards Membership and Training* (annual certification programs $15,000-$25,000 per company).

31. See *supra* Section VII.D (Product Liability — Cannabis Contamination Cases) in Cannabis Case Law Precedent Report (specialist report dated Dec. 23, 2024) (documenting 3-5 reported cannabis product liability cases annually nationwide; most settle confidentially).

32. *Bourgoin v. Twin Rivers Paper Co.*, 187 A.3d 10, 18 (Me. 2018) ("Federal illegality of cannabis does not bar state tort claims; state law governs product liability actions."); see also *Luna v. Harborside Health Center*, No. RG19009381 (Cal. Super. Ct. 2019) (California court rejected federal illegality defense).

33. Litigation materials provided during due diligence: *Complaint, Doe v. Pacific Cannabis Group*, Case No. RG24123456 (Super. Ct. Alameda County, filed Sept. 12, 2024); Target's *Settlement Demand Evaluation Memo* (Nov. 2024) (estimating settlement range $500K-$2M based on injury severity and precedent) (on file with counsel).

34. *Complaint, Doe v. Pacific Cannabis Group*, ¶¶ 12-18 (allegations regarding myclobutanil contamination and injury); Plaintiff's independent laboratory report by CannaSafe Analytics (Aug. 2024) (confirming myclobutanil presence at 1.8 μg/g) (on file with counsel).

35. *Complaint, Doe v. Pacific Cannabis Group*, ¶¶ 28-47 (claims for relief).

36. Target's *Answer and Affirmative Defenses, Doe v. Pacific Cannabis Group* (Oct. 2024) (asserting regulatory compliance defense, third-party lab negligence, causation challenges, and comparative fault) (on file with counsel).

37. *Anderson v. Owens-Corning Fiberglas Corp.*, 53 Cal. 3d 987, 1002 (1991) ("Compliance with regulatory standards is evidence of non-defectiveness but does not preclude liability if plaintiff proves product was unreasonably dangerous.").

38. *McCullough v. LivWell Enlightened Health*, No. 2018CV31234 (Colo. Dist. Ct. Denver County, filed Feb. 2018, settled Aug. 2019) (settlement terms confidential; estimated $800K-$1.5M based on case size and industry sources) (case materials on file with counsel).

39. *Doe v. [Cannabis Company Redacted]*, No. 20-2-12345-6 SEA (Wash. Super. Ct. King County, filed May 2020, settled Dec. 2020) (settlement $1.2M confirmed by industry sources; higher due to sale-to-minor regulatory violations) (sealed settlement materials on file with counsel).

40. Based on review of cannabis product liability settlements compiled from industry sources, insurance claim data, and confidential settlement communications in 12 cases between 2017-2024 (settlement data compilation on file with counsel).

41. Target's product liability insurance policy, Policy No. CPL-2024-00789, issued by Cannasure Insurance Company (eff. Jan. 1, 2024) (policy declares $10M aggregate, $2.5M per occurrence; pollution exclusion at § IV(g) may apply to pesticide claims); Insurer's reservation of rights letter dated Oct. 15, 2024 (on file with counsel).

42. *State-Licensed Cannabis Testing Laboratory Accuracy Study*, Journal of AOAC International, Vol. 106, No. 2, pp. 412-428 (March 2023) (peer-reviewed study of false negative rates in cannabis testing; range 0.1%-0.5% across contaminant categories).

43. NPV calculation: Pending case settlement $1,200,000 (Year 1) + ongoing annual exposure $300,000 × 3.605 (5-year annuity factor at 12% discount rate) = $1,200,000 + $1,081,500 = $2,281,500 total; assuming 50% insurance recovery on pending case yields net NPV $1,531,500, rounded to $1.53M.

44. Cal. Bus. & Prof. Code § 26070(a) (West 2024) ("A licensee shall notify the department within 24 hours if the licensee becomes aware that a cannabis product may present a health or safety risk to consumers.").

45. Cal. Code Regs. tit. 16, § 5056 (2024) (mandatory recall procedures); see also California Department of Cannabis Control, *Product Recall Procedures and Requirements* (guidance document, May 2023), available at https://cannabis.ca.gov/.

46. Recall cost estimates based on industry case studies: *2023 Cannabis Product Recall Cost Analysis*, Cannabis Industry Journal (Sept. 2023) (analyzing 24 recalls in California, Colorado, Oregon; median cost $75,000, range $50,000-$200,000 depending on distribution scope).

47. California Department of Cannabis Control, *Owner Change Application* (Form DCC-LIC-027, rev. 2024), Section 6 ("Disclose all product recalls issued by any regulatory authority in the past three years"); see also DCC *Owner Change Application Review Process*, *supra* note 24 (multiple recalls may result in conditional approval or denial).

48. Insurance broker quotations obtained during due diligence: Cannasure Insurance Company, *Product Liability Coverage Proposal* (Dec. 2024); MJ Insurance Services, *Cannabis Product Liability Market Analysis* (Nov. 2024) (both noting industry benchmarks $15M-$25M aggregate for MSOs with $200M-$400M revenue) (on file with counsel).

49. Premium estimate for additional $10M coverage: Cannasure Insurance Company quotation (Dec. 2024) ($150K-$300K premium for $10M layer excess of $10M primary, depending on loss history and quality control improvements) (on file with counsel).

50. Financial analysis indicating buyer should fund remediation post-closing based on: (1) 5.7x ROI calculation ($5.65M investment yields $32.4M NPV benefit); (2) operational control advantage (buyer has cultivation expertise and incentive to maximize quality); (3) purchase price reduction double-counts risk already reflected in reduced EBITDA multiple due to testing failures.

---

**SECTION SUMMARY**: 5,847 words | 50 footnotes | Severity: MEDIUM | Cross-references: 7 | Purchase price impact: $2M escrow allocation (product liability); quality control remediation ($5.65M) funded by buyer post-closing due to exceptional 5.7x ROI
